The very first clinical trials demonstrated the efficacy of the PARP inhibitor olaparib in breast and ovarian cancer patients carrying germline mutations in BRCA1/2, thus supporting the rationale for synthetic lethality (Fong et al. 2009; Audeh et al. 2010; Tutt et al. 2010). Here, BRCA1 is linked to ovarian cancer.